多发性骨髓瘤自体移植后MRD阴性预测因素及临床结局
研究纳入814例自体移植后达≥非常好的部分缓解的多发性骨髓瘤患者,48%实现MRD阴性;t(11;14)和移植前未达完全缓解独立预测MRD阳性;MRD阳性者PFS和OS更差,但t(11;14)阳性者MRD阴性率虽低,5年PFS与MRD阴性者相似。
要点
- 自体移植后48%患者实现MRD阴性,t(11;14)和移植前<CR独立预测MRD阳性。
- MRD阳性者PFS(HR 1.99)和OS(HR 1.62)均劣于MRD阴性者。
- t(11;14)阳性者即使MRD阳性,5年PFS与MRD阴性者相似(58% vs 63%)。
核心结论
- t(11;14)独立预测ASCT后MRD阳性,但不显著影响该亚组预后。
- MRD阳性者PFS和OS更差,且高危细胞遗传学异常数量影响PFS。
研究设计与样本
- 回顾性研究纳入2016年1月至2023年1月间814例ASCT后达≥VGPR并接受二代流式MRD评估的多发性骨髓瘤患者。
主要发现
- 387例(48%)ASCT后实现MRD阴性。
临床怎么用
- ASCT后应评估MRD状态,MRD阳性提示预后不良。
- 对于t(11;14)患者,MRD阳性并不显著影响预后,需结合其他因素判断。
- MRD阳性患者中,高危细胞遗传学异常数量和残留克隆浆细胞负荷可进一步分层PFS。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Measurable residual disease (MRD) is a powerful prognostic tool in multiple myeloma, but predictors of achieving MRD negativity after autologous stem cell transplantation (ASCT) are not well defined. We studied 814 patients who achieved at least a very good partial response after ASCT between January 2016 and January 2023 and underwent MRD assessment by next-generation flow cytometry. Overall, 387 (48%) achieved MRD negativity after ASCT. The presence of t(11;14) (odds ratio [OR], 2.1; 95% confidence interval [CI], 1.4-3.2; P< .01) and pretransplant response less than complete remission (OR, 2.1; 95% CI, 1.2-3.7; P< .01) independently predicted MRD positivity. Patients who were MRD positive had inferior progression-free survival (PFS; hazard ratio [HR], 1.99; 95% CI, 1.53-2.58; P< .001) and overall survival (HR, 1.62; 95% CI, 1.10-2.28; P = .009). Despite lower MRD-negative rate, 5-year PFS was similar among t(11;14) MRD positive (58%) and patients who were MRD negative (63%; P = .12). In patients who were MRD negative, the 5-year PFS was 73% in those without ≥2 HRCA compared with 55% in those with ≥2 HRCA (HR 1.9, 95% CI 1.2-3.3; P = .01). In the MRD-positive cohort, 5-year PFS was 53% in patients without ≥2 HRCA vs 17% in those with ≥2 HRCA (HR, 2.4; 95% CI, 1.6-3.6; P< .01). In addition, higher residual clonal plasma cell burden within MRD-positive disease was associated with inferior PFS (HR, 2.4; 95% CI, 1.2-6.9; P = .002). This study highlights that the presence of t(11;14) independently predicts MRD positivity after ASCT, although it does not significantly affect prognosis in this subgroup.
引用
- Bolarinwa A, Zanwar S, Abdallah N, et al. Predictors of posttransplant measurable residual disease negativity and impact on clinical outcomes in multiple myeloma. Blood Adv. 2026. PMID: 42508994. doi:10.1182/bloodadvances.2026020294
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。